iqvia weight loss drug prescriptions q3 2024 semaglutide tirzepatide The weight-loss boom has created massive market opportunities — and punishing failures. In this space, a single clinical trial result can send a stock soaring or instantly wipe out years of gains US FDA warns online vendors

The Flexibility of Tirzepatide Dosing Tirzepatide is a once-weekly injectable medication that belongs to a class of drugs known as dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonists

The results demonstrated that the protein expression of acyl-CoA synthetase long-chain family member 4 (ACSL4) NOX4 and COX2 got markedly elevated, while the GPX4 and FTH levels were overtly reduced in TPC-1-Lv-FTO compared with that of the vector group

Moisturizes the skin, helping address dryness

The first head-to-head clinical trial (SURMOUNT-5, published in NEJM 2025) showed tirzepatide produced 20.2% average weight loss at 72 weeks versus 13.7% for semaglutide approximately 47% greater relative weight loss

[1] This pharmacokinetic profile suggests that Zepbound itself is not inherently "hard on the kidneys" through direct nephrotoxic effects